Stage III Malignant Melanoma of Skin AJCC V6Phase 1/2NCT06152367
Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients
A Phase 1/2 study testing TAPCells vaccine in people with Stage III Malignant Melanoma of Skin AJCC V6 and Stage IV Malignant Melanoma of Skin, run by University of Chile at 1 site in Chile.
Trial summary
Implementing this protocol has its ethical justification in that patients with metastatic melanoma, once tumor invasion has reached beyond the lymph node barrier, cannot possibly be treated satisfactorily with traditional surgery methods, radiotherapy, or conventional available chemotherapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stage III Malignant Melanoma of Skin AJCC V6, Stage IV Malignant Melanoma of Skin
- What is being tested?
- TAPCells vaccine
- Type of treatment
- Vaccines
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 90 participants
- Where
- 1 siteChile
- Study dates
- 30 Jan 2001to 9 Oct 2004
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with histologically confirmed melanoma of the skin: Breslow, Clark, histological type. Location of the primary, clinical, or pathological regional status.
- Complete staging demonstrating the presence of distant metastases, either visceral or in soft tissues or bone tissue: Brain, Lung, Abdomen, and Pelvis CT and bone scintigraphy.
- Objectively measurable disease by clinical or radiological means
- Karnofsky's Performance Status is more significant than 70%
- Life expectancy greater than three months
- Patients over 18 years old
- Informed consent from the patient to participate in the protocol
Who cannot join
- Age greater than or equal to 65 years
- Ongoing active infections, including viral immunodeficiency
- Previous chemotherapy within less than two months
- Concomitant malignant tumors (e.g., Chronic Lymphocytic Leukemia, etc.)
- Uncontrolled concomitant diseases (Hypertension, unstable Diabetes mellitus, renal diseases requiring dialysis)
- Situations or conditions requiring urgent surgical intervention, such as intestinal obstruction due to metastasis
Show all 16Show fewer
- Pregnancy or lactation
- Concurrent participation in other therapeutic research protocols
- Any condition that compromises the objectives of this study.
- Removal Criteria from the Study:
- By the patient's decision to discontinue the study.
- Intolerable adverse reactions, according to WHO Criteria Grading Toxicities
- Intercurrent illness that may compromise the patient's life or interfere with the treatment study evaluation
- Requirements for concomitant medication that may interfere with study results.
- Failure to complete the study entirely
- Failure to follow up on the patient.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Phase I/II Trial In Stage III/IV Malignant Melanoma Using Autologous Dendritic Cells Loaded With Tumor Cell Lysates And Low Doses Of Proleukin
Implementing this protocol has its ethical justification in that patients with metastatic melanoma, once tumor invasion has reached beyond the lymph node barrier, cannot possibly be treated satisfactorily with traditional surgery methods, radiotherapy, or conventional available chemotherapy. The disseminated tumor is refractory to all standard treatments. Almost 100% of patients who develop distant metastases will die from their disease, either from complications or cachexia. Therefore, immunotherapy based on immunological stimulation with immunocompetent dendritic cells, added to immunological reinforcement with IL-2, can, according to the evidence emanating from ongoing clinical protocols, produce a prolongation of survival with better quality and, in some cases, with partial or total regression of the tumor.
General objective: It is to study the clinical and immunological response of patients treated with vaccines based on autologous dendritic cells loaded with tumor antigens, derived from allogeneic melanoma extracts, in combination or not, with intercalated low doses of recombinant human interleukin 2 (rhIL2) PROLEUKIN ® (aldesleukin). MAIN SPECIFIC OBJECTIVE: - SAFETY: Safety in administering dendritic cell preparation; local and systemic toxicity estimation. Determination of adverse reactions such as fever, nausea, allergy, neurological and cardiovascular symptoms. Local toxicity in the administration area. - MEASUREMENT OF THE IMMUNE RESPONSE: Based on in vivo and in vitro parameters: - In vivo response: Measure the type IV Delayed Hypersensitivity (DTH) response. It consists of a crossover test in which the response is compared to tissue interaction in vivo between dendritic cells sensitized with tumor extracts and their respective control unloaded dendritic cells. - In vitro response: ELISPOT assays, measurement of IFN-γ gamma production in peripheral blood of treated patients. Compare the specific immune response after each cycle of therapy through measurement of IFN-γ production by tumor-specific CTL. Cytotoxic radioactive chromium release assays to measure anti-tumor response mediated by CTL and NK. ELISA assays for quantifying cytokines (IFN-γ, IL-10) in patient serum after each cycle of therapy.
Read the detailed description
Vaccination of Melanoma Patients Using DCs Loaded with Allogeneic Melanoma Extracts.
In Chile, this study constitutes the first phase I clinical trial for treating advanced malignant melanoma using dendritic cell vaccines loaded with allogeneic tumor extracts complemented or not with low doses of rIL-2. Since chemotherapy and radiotherapy only offer palliative effects in advanced melanoma, resulting in an inferior prognosis for these patients, the trial intends to develop a protocol that would adapt to the reality of Chile, allowing for a combination of high technology and low costs.
After obtaining approval from the human research ethics committee from Universidad de Chile, 86 patients will be recruited who will be duly informed about the scope of these protocols and the realistic prospects of success. The participants then will undergo a comprehensive health check to assess their overall health. The participants will undergo a leukapheresis at the blood bank of the Clinical Hospital of the University de Chile. Peripheral blood mononuclear cells (PBMCs) will be separated using a Ficoll-Hypaque gradient in the laboratory of Antitumor Immunology at the Institute of Biomedical Sciences, Faculty of Medicine of the University de Chile. Some of the cells will be cryopreserved in liquid nitrogen for future use. Approximately 1.8x108 PBMCs will be placed in 6-well culture plates and incubated at 37°C and 7% CO2 for two hours. The suspended cells, peripheral blood lymphocytes (PBLs), will be removed and frozen for later use. The monocytes adhering to the plastic will be incubated for seven days in a serum-free culture medium (AIM-V therapeutic, GIBCO, BRL) in the presence of 500 U/ml of IL-4 and 800 U/ml of GM-CSF. On the sixth day, the DCs will be pulsed with tumor extracts from allogeneic melanoma cell lines, previously checked for sterility, and incubated for 6 hours at 37°C and 7% CO2, followed by maturation stimulus with TNF-alpha for 12 to 18 hours. Mature DCs will be characterized by flow cytometry. Approximately 10 to 20 x 106 pulsed DCs will be subcutaneously injected. This routine will be repeated weekly for at least four times and a maximum of 6 times. After the fourth dose, the participant's general condition, possible clinical regressions, adverse side effects, and the effects of the treatment on the immune system will be evaluated. This evaluation will be done through in vivo delayed-type hypersensitivity (DTH) assays using melanoma extracts and their respective controls. Planned in vitro assays for immune response measuring will include the detection of anti-melanoma CTL precursors by ELISPOT, cytokine production, proliferation assays, and quantifying the CD4/CD8 ratio by flow cytometry.
- Being tested
- TAPCells vaccine
- Medical subject headings
- Melanoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TAPCells vaccineBiological
Also called Proleukin
Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination.
| Study group | Role | What they receive |
|---|---|---|
| TAPCells | Experimental | Patients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination. Receives: Biological: TAPCells vaccine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of treatment-emergent adverse events [safety and tolerability]
Safety in administering dendritic cell preparations; Toxicity will be evaluated during every immunization and DTH test, using the NCI Common Terminology Criteria for Adverse Events Cancer Therapy Evaluation Program (CTCAE, Bethesda, MD, USA) v.3.0. In addition, patients will have a 24-h emergency phone number to report adverse events. Local and systemic toxicity estimation will be evaluated.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Local immune response measurement by DTH
Measuring the Delayed-Type Hypersensitivity response (DTH). It involves a cross-test comparing in vivo tissue response after injecting sc. tumor cell lysates used in the vaccine, PBS, or positive control antigenic mix. The test will be performed before the treatment and 30 days after the fourth dose. A positive DTH reaction is defined as skin erythema or induration ≥ 5 mm 48 hours after injection.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Systemic immune response measurement in PBMC
Measuring of multiple cytokine release (IFN-γ, IL-17, TGF-b, IL-10, and TNF-a) in patient PBMC subpopulations by flow cytometry analysis. Statistically significant increases in IFN-g and IL-17 will be considered positive immune responses. Increases in TGF-b, IL-10, and TNF-a will be considered tolerogenic responses. PBMC subpopulation analysis will be performed after in vitro re-stimulations.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Systemic IFN-γ response measurement in serum
Measuring of IFN-γ release in patient serum by ELISA assay. Statistically significant increases in IFN-g serum levels will be considered positive immune responses.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Systemic IL-17 response measurement in serum
Measuring of IL-17 release in patient serum by ELISA assay. Statistically significant increases in IL-17 serum levels will be considered positive immune responses.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Systemic TGF-b response measurement in serum
Measuring of TGF-b release in patient serum by ELISA assay. Statistically significant increases in TGF-b serum levels will be considered tolerogenic immune responses.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Systemic IL-10 response measurement in serum
Measuring of IL-10 release in patient serum by ELISA assay. Statistically significant increases in IL-10 serum levels will be considered tolerogenic immune responses.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Systemic TNF-a response measurement in serum
Measuring of TNF-a release in patient serum by ELISA assay. Statistically significant increases in TNF-a serum levels will be considered tolerogenic immune responses.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Systemic cytotoxic T cell-mediated tumor-specific IFN-g release
Measuring IFN-g production by tumor antigen in vitro-activated tumor-specific CTLs derived from peripheral blood of treated patients after each vaccine injection by IFN-g ELISPOT assays.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Systemic cytotoxic T cell-mediated anti-tumor cell cytotoxicity
Measuring cytotoxicity by tumor antigen in vitro activated tumor-specific CTLs derived from peripheral blood of treated patients after each vaccine injection by radioactive chromium releases cytotoxic assays.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Secondary outcomes (7)
Overall survival
Post-vaccination OS will be defined as the mean time that patients are still alive after the first vaccine dose injection using Kaplan-Meier survival analysis.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Progression-free survival
PFS is defined as the meantime that a patient showed stable disease after first vaccine dose.Time from treatment until disease recurrence (or death) using Kaplan-Meier survival analysis.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Clinical response measurement
To observe the objective response rate. Patients were defined as immunologic responders if they displayed activity against TRIMEL in DTH assays. Stable disease (SD) will be defined as less than 25% change in tumor size and absence of new lesions during a 6-week period. Inversely, progressive disease (PD) will be defined as more than 25% increase in the perpendicular diameter of any measurable tumor, appearance of new lesions by imaging examination, and/or worsening of general condition.
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Global health status scores measurement
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) is a 30-item questionnaire, validated in Chile in Spanish language, that will completed by the patients. It include both multi-item scales and single-item measures. It include five functional scales, three symptom scales, six single items, and a Global Health Status/Quality of Life (GHS/QoL) scale.
The GHS/QoL scale has seven possible response scores ranging from 1 (very poor) to 7 (excellent), which will be averaged and transformed to a 0-100 scale. A higher score on this scale indicated a better quality of life.
The change from baseline in GHS/QoL scores will be calculated. A positive change from baseline indicated improvement in the patient's quality of life.
Measured: Evaluated at immunization 1 (day 0; baseline level), 3 (day 20) and 4 (day 50), and also at DTH test (day 80)
Physical functioning scale scores measurement
The EORTC QLQ-C30 pain symptom scale is one of the symptom scales in the questionnaire, which measured the severity of pain experienced by the patient. The pain symptom scale consist in two items, one measuring the severity of pain and the other measuring the use of painkillers. The items will be rated on a 4-point scale ranging from 1="not at all" to 4="very much". The scores for each item will be summed and transformed to a 0 to 100 scale (higher scores indicating more severe pain).
The change from baseline in pain symptom scale scores will be calculated. A negative change from baseline indicated improvement.
Measured: Evaluated at immunization 1 (day 0; baseline level), 3 (day 20) and 4 (day 50), and also at DTH test (day 80)
Pain symptom scale scores measurement
The EORTC QLQ-C30 physical functioning scale measures a patient's ability to carry out daily activities and tasks requiring physical exertion. It consist in five questions asking patients to rate their level of physical functioning, with response options ranging from 1="not at all" to 4="very much". The scores for each item will summed and transformed to a 0 to 100 scale, with higher scores indicating better physical functioning.
The change from baseline in physical functioning scale scores will be calculated. A positive change from baseline indicated improvement in physical functioning.The GHS/QoL scale has seven possible response scores ranging from 1 (very poor) to 7 (excellent), which will be averaged and transformed to a 0-100 scale. A higher score on this scale indicated a better quality of life.
The change from baseline in GHS/QoL scores will be calculated. A positive change from baseline indicated improvement in the patient's quality of life.
Measured: Evaluated at immunization 1 (day 0; baseline level), 3 (day 20) and 4 (day 50), and also at DTH test (day 80)
Performance status response
Percentage of patients with a 20% or more significant increase in activity measured by the Karnofsky index
Measured: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Nov 2023
- Study start30 Jan 2001
- Primary completion9 Oct 2004
- Study completion9 Oct 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Stage III Malignant Melanoma of Skin AJCC V6Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 90 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Chile
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Flavio Salazar-Onfray, PhD, Principal investigator, FACULTY OF MEDICINE, Universidad de Chile
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06152367
- Sponsor's protocol ID
- UCHD04T2026
- Status last verified
- Nov 2023
- First submitted
- 27 Sep 2023
- Last updated
- 30 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Aguilera R, Saffie C, Tittarelli A, Gonzalez FE, Ramirez M, Reyes D, Pereda C, Hevia D, Garcia T, Salazar L, Ferreira A, Hermoso M, Mendoza-Naranjo A, Ferrada C, Garrido P, Lopez MN, Salazar-Onfray F. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res. 2011 Apr 15;17(8):2474-83. doi: 10.1158/1078-0432.CCR-10-2384. Epub 2011 Feb 3.
PubMed 21292818Duran-Aniotz C, Segal G, Salazar L, Pereda C, Falcon C, Tempio F, Aguilera R, Gonzalez R, Perez C, Tittarelli A, Catalan D, Nervi B, Larrondo M, Salazar-Onfray F, Lopez MN. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. Cancer Immunol Immunother. 2013 Apr;62(4):761-72. doi: 10.1007/s00262-012-1377-3. Epub 2012 Dec 15.
PubMed 23242374Tittarelli A, Gonzalez FE, Pereda C, Mora G, Munoz L, Saffie C, Garcia T, Diaz D, Falcon C, Hermoso M, Lopez MN, Salazar-Onfray F. Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients. Cancer Immunol Immunother. 2012 Nov;61(11):2067-77. doi: 10.1007/s00262-012-1268-7. Epub 2012 May 3.
PubMed 22552381Garcia-Salum T, Villablanca A, Matthaus F, Tittarelli A, Baeza M, Pereda C, Gleisner MA, Gonzalez FE, Lopez MN, Hoheisel JD, Norgauer J, Gebicke-Haerter PJ, Salazar-Onfray F. Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy. Oncotarget. 2018 Mar 30;9(24):17014-17027. doi: 10.18632/oncotarget.24795. eCollection 2018 Mar 30.
PubMed 29682201Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE, Escobar A, Ginesta A, Reyes D, Gonzalez R, Mendoza-Naranjo A, Larrondo M, Compan A, Ferrada C, Salazar-Onfray F. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol. 2009 Feb 20;27(6):945-52. doi: 10.1200/JCO.2008.18.0794. Epub 2009 Jan 12.
PubMed 19139436
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase I/II Trial In Stage III/IV Malignant Melanoma Using Autologous Dendritic Cells Loaded With Tumor Cell Lysates And Low Doses Of Proleukin
- ClinicalTrials.gov ID
- NCT06152367
- Acronym / sponsor ID
- UCHD04T2026
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 90 participants (actual)
- Lead sponsor
- University of ChileUniversity, hospital or other
- Study start
- 30 Jan 2001 (actual)
- Primary completion
- 9 Oct 2004 (actual)
- Study completion
- 9 Oct 2004 (actual)
- First posted
- 30 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Implementing this protocol has its ethical justification in that patients with metastatic melanoma, once tumor invasion has reached beyond the lymph node barrier, cannot possibly be treated satisfactorily with traditional surgery methods, radiotherapy, or conventional available chemotherapy. The disseminated tumor is refractory to all standard treatments. Almost 100% of patients who develop distant metastases will die from their disease, either from complications or cachexia. Therefore, immunotherapy based on immunological stimulation with immunocompetent dendritic cells, added to immunological reinforcement with IL-2, can, according to the evidence emanating from ongoing clinical protocols, produce a prolongation of survival with better quality and, in some cases, with partial or total regression of the tumor.
General objective: It is to study the clinical and immunological response of patients treated with vaccines based on autologous dendritic cells loaded with tumor antigens, derived from allogeneic melanoma extracts, in combination or not, with intercalated low doses of recombinant human interleukin 2 (rhIL2) PROLEUKIN ® (aldesleukin). MAIN SPECIFIC OBJECTIVE: - SAFETY: Safety in administering dendritic cell preparation; local and systemic toxicity estimation. Determination of adverse reactions such as fever, nausea, allergy, neurological and cardiovascular symptoms. Local toxicity in the administration area. - MEASUREMENT OF THE IMMUNE RESPONSE: Based on in vivo and in vitro parameters: - In vivo response: Measure the type IV Delayed Hypersensitivity (DTH) response. It consists of a crossover test in which the response is compared to tissue interaction in vivo between dendritic cells sensitized with tumor extracts and their respective control unloaded dendritic cells. - In vitro response: ELISPOT assays, measurement of IFN-γ gamma production in peripheral blood of treated patients. Compare the specific immune response after each cycle of therapy through measurement of IFN-γ production by tumor-specific CTL. Cytotoxic radioactive chromium release assays to measure anti-tumor response mediated by CTL and NK. ELISA assays for quantifying cytokines (IFN-γ, IL-10) in patient serum after each cycle of therapy.
Detailed description
Vaccination of Melanoma Patients Using DCs Loaded with Allogeneic Melanoma Extracts.
In Chile, this study constitutes the first phase I clinical trial for treating advanced malignant melanoma using dendritic cell vaccines loaded with allogeneic tumor extracts complemented or not with low doses of rIL-2. Since chemotherapy and radiotherapy only offer palliative effects in advanced melanoma, resulting in an inferior prognosis for these patients, the trial intends to develop a protocol that would adapt to the reality of Chile, allowing for a combination of high technology and low costs.
After obtaining approval from the human research ethics committee from Universidad de Chile, 86 patients will be recruited who will be duly informed about the scope of these protocols and the realistic prospects of success. The participants then will undergo a comprehensive health check to assess their overall health. The participants will undergo a leukapheresis at the blood bank of the Clinical Hospital of the University de Chile. Peripheral blood mononuclear cells (PBMCs) will be separated using a Ficoll-Hypaque gradient in the laboratory of Antitumor Immunology at the Institute of Biomedical Sciences, Faculty of Medicine of the University de Chile. Some of the cells will be cryopreserved in liquid nitrogen for future use. Approximately 1.8x108 PBMCs will be placed in 6-well culture plates and incubated at 37°C and 7% CO2 for two hours. The suspended cells, peripheral blood lymphocytes (PBLs), will be removed and frozen for later use. The monocytes adhering to the plastic will be incubated for seven days in a serum-free culture medium (AIM-V therapeutic, GIBCO, BRL) in the presence of 500 U/ml of IL-4 and 800 U/ml of GM-CSF. On the sixth day, the DCs will be pulsed with tumor extracts from allogeneic melanoma cell lines, previously checked for sterility, and incubated for 6 hours at 37°C and 7% CO2, followed by maturation stimulus with TNF-alpha for 12 to 18 hours. Mature DCs will be characterized by flow cytometry. Approximately 10 to 20 x 106 pulsed DCs will be subcutaneously injected. This routine will be repeated weekly for at least four times and a maximum of 6 times. After the fourth dose, the participant's general condition, possible clinical regressions, adverse side effects, and the effects of the treatment on the immune system will be evaluated. This evaluation will be done through in vivo delayed-type hypersensitivity (DTH) assays using melanoma extracts and their respective controls. Planned in vitro assays for immune response measuring will include the detection of anti-melanoma CTL precursors by ELISPOT, cytokine production, proliferation assays, and quantifying the CD4/CD8 ratio by flow cytometry.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| TAPCells | Experimental | Biological: TAPCells vaccinePatients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients with histologically confirmed melanoma of the skin: Breslow, Clark, histological type. Location of the primary, clinical, or pathological regional status.
- Complete staging demonstrating the presence of distant metastases, either visceral or in soft tissues or bone tissue: Brain, Lung, Abdomen, and Pelvis CT and bone scintigraphy.
- Objectively measurable disease by clinical or radiological means
- Karnofsky's Performance Status is more significant than 70%
- Life expectancy greater than three months
Key exclusion criteria (16 listed)
- Age greater than or equal to 65 years
- Ongoing active infections, including viral immunodeficiency
- Previous chemotherapy within less than two months
- Concomitant malignant tumors (e.g., Chronic Lymphocytic Leukemia, etc.)
- Uncontrolled concomitant diseases (Hypertension, unstable Diabetes mellitus, renal diseases requiring dialysis)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TAPCells vaccineAlso: ProleukinPatients are immunized with four doses of TAPCells (20x106), days 0, 10, 20, and 50 complemented with low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c. days 2, 3, and 4 after a second, third, and fourth vaccination. | Biological | TAPCells |
Primary outcome
Incidence of treatment-emergent adverse events [safety and tolerability]
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Safety in administering dendritic cell preparations; Toxicity will be evaluated during every immunization and DTH test, using the NCI Common Terminology Criteria for Adverse Events Cancer Therapy Evaluation Program (CTCAE, Bethesda, MD, USA) v.3.0. In addition, patients will have a 24-h emergency phone number to report adverse events. Local and systemic toxicity estimation will be evaluated.
Local immune response measurement by DTH
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Measuring the Delayed-Type Hypersensitivity response (DTH). It involves a cross-test comparing in vivo tissue response after injecting sc. tumor cell lysates used in the vaccine, PBS, or positive control antigenic mix. The test will be performed before the treatment and 30 days after the fourth dose. A positive DTH reaction is defined as skin erythema or induration ≥ 5 mm 48 hours after injection.
Systemic immune response measurement in PBMC
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Measuring of multiple cytokine release (IFN-γ, IL-17, TGF-b, IL-10, and TNF-a) in patient PBMC subpopulations by flow cytometry analysis. Statistically significant increases in IFN-g and IL-17 will be considered positive immune responses. Increases in TGF-b, IL-10, and TNF-a will be considered tolerogenic responses. PBMC subpopulation analysis will be performed after in vitro re-stimulations.
Systemic IFN-γ response measurement in serum
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Measuring of IFN-γ release in patient serum by ELISA assay. Statistically significant increases in IFN-g serum levels will be considered positive immune responses.
Systemic IL-17 response measurement in serum
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Measuring of IL-17 release in patient serum by ELISA assay. Statistically significant increases in IL-17 serum levels will be considered positive immune responses.
Systemic TGF-b response measurement in serum
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Measuring of TGF-b release in patient serum by ELISA assay. Statistically significant increases in TGF-b serum levels will be considered tolerogenic immune responses.
Systemic IL-10 response measurement in serum
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Measuring of IL-10 release in patient serum by ELISA assay. Statistically significant increases in IL-10 serum levels will be considered tolerogenic immune responses.
Systemic TNF-a response measurement in serum
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Measuring of TNF-a release in patient serum by ELISA assay. Statistically significant increases in TNF-a serum levels will be considered tolerogenic immune responses.
Systemic cytotoxic T cell-mediated tumor-specific IFN-g release
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Measuring IFN-g production by tumor antigen in vitro-activated tumor-specific CTLs derived from peripheral blood of treated patients after each vaccine injection by IFN-g ELISPOT assays.
Systemic cytotoxic T cell-mediated anti-tumor cell cytotoxicity
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Measuring cytotoxicity by tumor antigen in vitro activated tumor-specific CTLs derived from peripheral blood of treated patients after each vaccine injection by radioactive chromium releases cytotoxic assays.
7 secondary outcomes
Overall survival
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Progression-free survival
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Clinical response measurement
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Global health status scores measurement
Time frame: Evaluated at immunization 1 (day 0; baseline level), 3 (day 20) and 4 (day 50), and also at DTH test (day 80)
Physical functioning scale scores measurement
Time frame: Evaluated at immunization 1 (day 0; baseline level), 3 (day 20) and 4 (day 50), and also at DTH test (day 80)
Pain symptom scale scores measurement
Time frame: Evaluated at immunization 1 (day 0; baseline level), 3 (day 20) and 4 (day 50), and also at DTH test (day 80)
Performance status response
Time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2023.
- Background: PubMed 21292818Aguilera R, Saffie C, Tittarelli A, Gonzalez FE, Ramirez M, Reyes D, Pereda C, Hevia D, Garcia T, Salazar L, Ferreira A, Hermoso M, Mendoza-Naranjo A, Ferrada C, Garrido P, Lopez MN, Salazar-Onfray F. Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells. Clin Cancer Res. 2011 Apr 15;17(8):2474-83. doi: 10.1158/1078-0432.CCR-10-2384. Epub 2011 Feb 3.
- Background: PubMed 23242374Duran-Aniotz C, Segal G, Salazar L, Pereda C, Falcon C, Tempio F, Aguilera R, Gonzalez R, Perez C, Tittarelli A, Catalan D, Nervi B, Larrondo M, Salazar-Onfray F, Lopez MN. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. Cancer Immunol Immunother. 2013 Apr;62(4):761-72. doi: 10.1007/s00262-012-1377-3. Epub 2012 Dec 15.
- Background: PubMed 22552381Tittarelli A, Gonzalez FE, Pereda C, Mora G, Munoz L, Saffie C, Garcia T, Diaz D, Falcon C, Hermoso M, Lopez MN, Salazar-Onfray F. Toll-like receptor 4 gene polymorphism influences dendritic cell in vitro function and clinical outcomes in vaccinated melanoma patients. Cancer Immunol Immunother. 2012 Nov;61(11):2067-77. doi: 10.1007/s00262-012-1268-7. Epub 2012 May 3.
- Background: PubMed 29682201Garcia-Salum T, Villablanca A, Matthaus F, Tittarelli A, Baeza M, Pereda C, Gleisner MA, Gonzalez FE, Lopez MN, Hoheisel JD, Norgauer J, Gebicke-Haerter PJ, Salazar-Onfray F. Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy. Oncotarget. 2018 Mar 30;9(24):17014-17027. doi: 10.18632/oncotarget.24795. eCollection 2018 Mar 30.
- Results publication: PubMed 19139436Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE, Escobar A, Ginesta A, Reyes D, Gonzalez R, Mendoza-Naranjo A, Larrondo M, Compan A, Ferrada C, Salazar-Onfray F. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol. 2009 Feb 20;27(6):945-52. doi: 10.1200/JCO.2008.18.0794. Epub 2009 Jan 12.
- Individual participant dataSharing planned: No
Related trials for Stage III Malignant Melanoma of Skin AJCC V6
RecruitingPhase 2
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Active, not recruitingPhase 2
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
Acral Lentiginous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8
Active, not recruitingPhase 2
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis
Melanoma Stage III, Melanoma Stage IV
Active, not recruitingPhase 2/3
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Active, not recruitingPhase 3
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Flavio Salazar-Onfray, PhD principal investigator
FACULTY OF MEDICINE, Universidad de Chile
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing TAPCells vaccine in people with Stage III Malignant Melanoma of Skin AJCC V6 and Stage IV Malignant Melanoma of Skin, run by University of Chile at 1 site in Chile.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of treatment-emergent adverse events [safety and tolerability] (time frame: Every four weeks the first year after treatment. Every two months during the second year after treatment.). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06152367, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2023.